XBIO News and Press, Xenetic Biosciences Inc. From 06/02/22

- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET - FRENCHTOWN, NJ / ACCESSWIRE / June 2, 2022 / JTC Team ("JTC"), a fully integrated corporate c...

Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9 th at 11:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / June 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or ...

Live Webcast Presentation on Wednesday, May 25 th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatmen...

- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities - DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indication...

Xenetic Biosciences (NASDAQ:XBIO) signed exclusive license and sublicense agreements with CLS Therapeutics to develop its interventional DNase based oncology platform aimed at improving existing treatments, including immunotherapies. Under the agreements, Xenetic has an exclusive license to C...

Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunity DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor ind...

Xenetic Biosciences press release (NASDAQ:XBIO): FY GAAP EPS of -$0.55. Revenue of $1.16M (+163.6% Y/Y). The Company ended the year with approximately $18.2 million of cash. 10K For further details see: Xenetic Biosciences GAAP EPS of -$0.55, revenue of $1.16M

- XCART TM continuing to advance toward IND-enabling studies - PolyXen® platform technology growing royalty stream through license agreement - Closed the year with $18.2 million of cash FRAMINGHAM, MA / ACCESSWIRE / March 23, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XB...

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrate...

Xenetic Biosciences (NASDAQ:XBIO): Q3 GAAP EPS of -$0.13 misses by $0.01. Revenue of $0.35M (+191.7% Y/Y) beats by $0.15M. Press Release For further details see: Xenetic Biosciences EPS misses by $0.01, beats on revenue